Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

uropean investors including Forbion Capital Partners, Sofinnova Partners, Abingworth Management, The Wellcome Trust, GIMV and Credit Agricole Private Equity.

FOVEA has built a project portfolio including internal research programs on dry AMD, glaucoma (neuroprotection), retinal dystrophies as well as clinical programs underway for such indications as macular edema, allergic conjunctivitis, or retinitis pigmentosa.

To advance the development and commercialization of its programs, FOVEA is working both independently and through collaborators including industrial partners like Novartis, Genzyme, CombinatoRx, as well as with academic teams, like the Inserm unit U592, the Rothschild Ophthalmological Foundation, or the Johns Hopkins University.

For additional information about FOVEA and its programs, please visit http://www.fovea-pharma.com

About Forbion Capital Partners

Forbion Capital Partners invests in EU and US Life Sciences companies, developing world-class products and technologies. The Forbion team has invested in 38 drug development and med tech companies since 2000, initially as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December of 2006 the group became independent by broadening its investor base and changing its name to Forbion Capital Partners. In recent years, the Forbion team has successfully divested from 13 portfolio companies leaving an active portfolio of 25 companies. Assets under management currently exceed EUR200 M.

Fovea Pharmaceuticals SA

Bernard Davitian

Chief Financial Officer

+33144164261

info@fovea-pharma.com

Press Contacts :

France U.S.

EuroRSCG C&O Russo Partners, LLC

Marie Carole de Groc Wendy Lau

+33158479507 +1-212-845-4272


SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... Scottsdale, AZ (PRWEB) August 19, 2014 ... the launch of its online sales skills training ... their sales skills. , MedTech clinical staff spend the ... at a hospital, standalone medical center, or physician practice ... administrative staff. But why stop there? Sales Horizons believes ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... and their Owners, ROCKVILLE, Md., June 23 ... a retriever retrieve? Why do Yorkshire terriers live,longer than ... be related,to a Great Dane?, (Photo: http://www.newscom.com/cgi-bin/prnh/20080623/AQM507 ... length and behavior more than any,other animal, and until ...
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Event June 27-28, 2008, NOVATO, Calif., June ... (OTC Bulletin Board:,RPTP), today announced that Ted Daley, ... Cystinosis Foundation Ireland,s 5th,International Cystinosis Conference to be ... City, Charlemont Place, Dublin 2, in Dublin, Ireland., ...
Cached Biology Technology:DNA Study Unlocks Mystery to Diverse Traits in Dogs 2DNA Study Unlocks Mystery to Diverse Traits in Dogs 3Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... new gene therapy developed by researchers at the University ... protect mice from a life-threatening heart condition caused by ... avenue," said Yi Lai, Ph.D., the leading author of ... School of Medicine,s Department of Molecular Microbiology and Immunology. ... this could lead to a treatment for people with ...
(Date:8/20/2014)... (PS1) absorbs light and its energy is finally ... biomass. Photovoltaic devices, mostly build from silicon based ... One approach for the development of cheaper and ... the isolated membrane protein complexes of photosynthesis. Prof. ... PS1 from thermophilic cyanobacteria that live in a ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... John Bell said QUT had worked with a Canberra-based company ... both windows and energy generators in houses or commercial buildings. ... significant difference to home and building owners energy costs and ... on onsold. Professor Bell said the glass was one ...
... dramatically reduce damage caused by strokes the UK National ... (10 April). Speaking at the conference in Edinburgh, ... explain how combining scaffold microparticles with neural stem cells ... temporary loss of blood supply to the brain which ...
... 9, 2008) A study published in the April ... suggests an association between high egg consumption and all-cause mortality, ... an explanation. The researchers, Djouss and Gaziano, analyzed data from ... a 20 year period. The fact is, healthy adults ...
Cached Biology News:Scientists ask whether microscaffolding can help stem cells rebuild brain after stroke damage 2Statement by the American Egg Board and Egg Nutrition Center on AJCN study on egg consumption 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... Source: Pseudomonas atlantica Description: Beta-Agarase is ... fragments from low-melting-temperature agarose. Beta-Agarase digests ... Tested User Friendly Properties: Heat Inactivation: ... Da Optimum pH: 6.5 Purity: Tested ...
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
...
Biology Products: